To investigate the effect of anti-angiogenic therapy on leukocyte infiltration into tumors, primary renal cell carcinoma (RCC) tissues were obtained from patients treated with neoadjuvant VEGF-targeted therapy [35, 37, 42]. This evidence concerns the gene VEGFA and renal cell carcinoma.